Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Nuklearmedizin - NuclearMedicine | April 2, 2026 | Volume: 65 | Issue: 02 | Pages: 107-107
10.1055/s-0046-1818191